Geron Corporation [NASDAQ: GERN] loss 0.00% on the last trading session, reaching $2.45 price per share at the time. The company report on September 7, 2023 at 8:00 AM that Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic Oncology Annual Meeting (SOHO) held in Houston, Texas and virtually.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
“For imetelstat-treated patients in the IMerge Phase 3 trial, the durability of transfusion independence, substantial increases in hemoglobin, robust treatment effect across subgroups and improvement in fatigue, along with a manageable safety profile, represent, we believe, an unparalleled clinical benefit in lower risk MDS,” said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron. “It was particularly meaningful for these data to be presented at SOHO, where there was a broad array of professionals who touch the lives of patients with lower risk MDS.”.
Geron Corporation represents 547.28 million in outstanding shares, while the company has a total market value of $1.26 billion with the latest information. GERN stock price has been found in the range of $2.42 to $2.50.
If compared to the average trading volume of 5.39M shares, GERN reached a trading volume of 4384898 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Geron Corporation [GERN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GERN shares is $4.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GERN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2023.
The Average True Range (ATR) for Geron Corporation is set at 0.14, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 2512.82. The Price to Book ratio for the last quarter was 4.45, with the Price to Cash per share for the same quarter was set at 0.72.
Trading performance analysis for GERN stock
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.94. With this latest performance, GERN shares dropped by -17.23% in over the last four-week period, additionally sinking by -13.12% over the last 6 months – not to mention a drop of -3.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 39.96, with the RSI for the last a single of trading hit 42.44, and the three-weeks RSI is set at 39.96 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 2.90, while it was recorded at 2.45 for the last single week of trading, and 2.76 for the last 200 days.
Geron Corporation [GERN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -23246.64 and a Gross Margin at -45.64. Geron Corporation’s Net Margin is presently recorded at -23808.89.
Return on Total Capital for GERN is now -87.37, given the latest momentum, and Return on Invested Capital for the company is -96.40. Return on Equity for this stock declined to -137.49, with Return on Assets sitting at -68.12. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 69.69. Additionally, GERN Total Debt to Total Capital is recorded at 41.07, with Total Debt to Total Assets ending up at 29.26. Long-Term Debt to Equity for the company is recorded at 42.35, with the Long-Term Debt to Total Capital now at 24.96.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,326,178 per employee. Receivables Turnover for the company is 0.24 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
Geron Corporation [GERN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
An analysis of Institutional ownership at Geron Corporation [GERN]
The top three institutional holders of GERN stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in GERN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in GERN stock with ownership which is approximately 5.7381%.
